Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
No treatment for frontotemporal dementia (FTD), the second most common type of early-onset dementia, is available, but therapeutics are being investigated to target the 2 main proteins associated with FTD pathological subtypes: TDP-43 (FTLD-TDP) and tau (FTLD-tau). Testing potential therapies in clinical trials is hampered by our inability to distinguish between patients with FTLD-TDP and FTLD-tau. Therefore, we evaluated truncated stathmin-2 (STMN2) as a proxy of TDP-43 pathology, given the reports that TDP-43 dysfunction causes truncated STMN2 accumulation. Truncated STMN2 accumulated in human induced pluripotent stem cell-derived neurons depleted of TDP-43, but not in those with pathogenic TARDBP mutations in the absence of TDP-43 aggregation or loss of nuclear protein. In RNA-Seq analyses of human brain samples from the NYGC ALS cohort, truncated STMN2 RNA was confined to tissues and disease subtypes marked by TDP-43 inclusions. Last, we validated that truncated STMN2 RNA was elevated in the frontal cortex of a cohort of patients with FTLD-TDP but not in controls or patients with progressive supranuclear palsy, a type of FTLD-tau. Further, in patients with FTLD-TDP, we observed significant associations of truncated STMN2 RNA with phosphorylated TDP-43 levels and an earlier age of disease onset. Overall, our data uncovered truncated STMN2 as a marker for TDP-43 dysfunction in FTD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trimmomatic: a flexible trimmer for Illumina sequence data
Bolger, A. M., Lohse, M., & Usadel, B. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu170 · Cited by 65,548 · cited 1×
“36) (54), all samples were aligned to the hg38 build (GRCh38.”
BackgroundThe Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364 · cited 2×
“Age at death (yr) 82 (55, 99) 69 (52, 86) 72 (49, 100) 76 (50, 100) 67 (49, 98) 74 (60, 84) 63 (61, 64)”
Methodfastp: an ultra-fast all-in-one FASTQ preprocessor
Chen, S., Zhou, Y., Chen, Y., & Gu, J. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty560 · Cited by 29,721 · cited 1×
“fastp (47) and aligned to the hg38 build (GRCh38.”
BackgroundfeatureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219 · cited 2×
“Age at death (yr) 82 (55, 99) 69 (52, 86) 72 (49, 100) 76 (50, 100) 67 (49, 98) 74 (60, 84) 63 (61, 64)”
MethodRSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179
MultiQC: summarize analysis results for multiple tools and samples in a single report
Ewels, P., Magnusson, M., Lundin, S., & Käller, M. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw354 · Cited by 10,143 · cited 2×
“Ewels P, Magnusson M, Lundin S, Kaller M. MultiQC: summarize analysis results for multiple tools and samples in a single report.”
MethodUbiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis
Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., Bruce, J., Schuck, T., Grossman, M., Clark, C. M., et al. (2006) · Science · doi:10.1126/science.1134108 · Cited by 6,576 · cited 1×
“Cells with TDP-43 pathology feature a redistribution of TDP-43 from the nucleus to the cytoplasm, where TDP-43 is ubiquitinated, hyperphosphorylated, and cleaved into C-terminal fragments (14).”
BackgroundThe GTEx Consortium atlas of genetic regulatory effects across human tissues
The GTEx Consortium, Aguet, F., Anand, S., Ardlie, K. G., Gabriel, S., Getz, G. A., Graubert, A., Hadley, K., Handsaker, R. E., Huang, K. H., et al. (2020) · Science · doi:10.1126/science.aaz1776 · Cited by 5,547 · cited 3×
“the criteria of the Genotype Tissue Expression Consortium (64).”
BackgroundSelf-citationNextflow enables reproducible computational workflows
Di Tommaso, P., Chatzou, M., Floden, E. W., Barja, P. P., Palumbo, E., & Notredame, C. (2017) · Nature Biotechnology · doi:10.1038/nbt.3820 · Cited by 4,001
GENCODE reference annotation for the human and mouse genomes
Frankish, A., Diekhans, M., Ferreira, A.-M., Johnson, R., Jungreis, I., Loveland, J., Mudge, J. M., Sisu, C., Wright, J., Armstrong, J., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky955 · Cited by 3,040 · cited 2×
“2a) (48), with indexes created from GENCODE, version 30 (55).”
MethodSnakemake—a scalable bioinformatics workflow engine
Köster, J., & Rahmann, S. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts480 · Cited by 2,780
Arai, T., Hasegawa, M., Akiyama, H., Ikeda, K., Nonaka, T., Mori, H., Mann, D., Tsuchiya, K., Yoshida, M., Hashizume, Y., et al. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.10.093 · Cited by 2,732
TDP-43 Mutations in Familial and Sporadic Amyotrophic Lateral Sclerosis
Sreedharan, J., Blair, I. P., Tripathi, V. B., Hu, X., Vance, C., Rogelj, B., Ackerley, S., Durnall, J. C., Williams, K. L., Buratti, E., et al. (2008) · Science · doi:10.1126/science.1154584 · Cited by 2,630 · cited 2×
“Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis.”
BackgroundThe RIN: an RNA integrity number for assigning integrity values to RNA measurements
Schroeder, A., Mueller, O., Stocker, S., Salowsky, R., Leiber, M., Gassmann, M., Lightfoot, S., Menzel, W., Granzow, M., & Ragg, T. (2006) · BMC Molecular Biology · doi:10.1186/1471-2199-7-3 · Cited by 2,623
Converging Mechanisms in ALS and FTD: Disrupted RNA and Protein Homeostasis
Ling, S.-C., Polymenidou, M., & Cleveland, D. W. (2013) · Neuron · doi:10.1016/j.neuron.2013.07.033 · Cited by 1,811 · cited 2×
“org Volume 130 Number 11 November 2020 Introduction Tar DNA-binding protein 43 (TDP-43) regulates multiple aspects of RNA metabolism, including RNA stabilization, transcription, splicing, and transport (1).”
BackgroundAnalysis and design of RNA sequencing experiments for identifying isoform regulation
Katz, Y., Wang, E. T., Airoldi, E. M., & Burge, C. B. (2010) · Nature Methods · doi:10.1038/nmeth.1528 · Cited by 1,353 · cited 2×
“The relative abundance of truncated STMN2 as a proportion of total STMN2 was expressed in terms of percent spliced in (PSI) (51).”
BackgroundLong pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43
Polymenidou, M., Lagier-Tourenne, C., Hutt, K. R., Huelga, S. C., Moran, J., Liang, T. Y., Ling, S.-C., Sun, E., Wancewicz, E., Mazur, C., et al. (2011) · Nature Neuroscience · doi:10.1038/nn.2779 · Cited by 1,335 · cited 2×
“TDP-43 binds thousands of RNAs (2, 3) and, for particular genes, represses nonconserved cryptic exons in a species- (4) and cell-type–specific manner (5, 6).”
BackgroundCharacterizing the RNA targets and position-dependent splicing regulation by TDP-43
Tollervey, J. R., Curk, T., Rogelj, B., Briese, M., Cereda, M., Kayikci, M., König, J., Hortobágyi, T., Nishimura, A. L., Župunski, V., et al. (2011) · Nature Neuroscience · doi:10.1038/nn.2778 · Cited by 1,165 · cited 2×
“TDP-43 binds thousands of RNAs (2, 3) and, for particular genes, represses nonconserved cryptic exons in a species- (4) and cell-type–specific manner (5, 6).”
BackgroundSelf-citationBang, J., Spina, S., & Miller, B. L. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00461-4 · Cited by 1,144
A harmonized classification system for FTLD-TDP pathology
Mackenzie, I. R. A., Neumann, M., Baborie, A., Sampathu, D. M., Du Plessis, D., Jaros, E., Perry, R. H., Trojanowski, J. Q., Mann, D. M. A., & Lee, V. M. Y. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0845-8 · Cited by 1,017 · cited 1×
“Furthermore, some FTLD-TDP subtypes are associated with particular mutations (20, 25, 26).”
BackgroundTDP‐43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease
Amador‐Ortiz, C., Lin, W., Ahmed, Z., Personett, D., Davies, P., Duara, R., Graff‐Radford, N. R., Hutton, M. L., & Dickson, D. W. (2007) · Annals of Neurology · doi:10.1002/ana.21154 · Cited by 916 · cited 1×
“Indeed, up to 67% of patients with AD develop TDP-43 inclusions and, compared to AD patients without TDP-43 pathology, they are cognitively and functionally worse, suggesting that abnormal TDP-43 causes a modified AD phenotype (37-46).”
BackgroundSelf-citationAnnotation-free quantification of RNA splicing using LeafCutter
Li, Y. I., Knowles, D. A., Humphrey, J., Barbeira, A. N., Dickinson, S. P., Im, H. K., & Pritchard, J. K. (2018) · Nature Genetics · doi:10.1038/s41588-017-0004-9 · Cited by 765 · cited 3×
“Junctions from each sample were then clustered together using LeafCutter (70) with relaxed junction filtering (minimum total reads per junction = 30, minimum fraction of total cluster reads = 0.”
MethodInfluentialSelf-citationTDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD
Ling, J. P., Pletnikova, O., Troncoso, J. C., & Wong, P. C. (2015) · Science · doi:10.1126/science.aab0983 · Cited by 688 · cited 1×
“TDP-43 binds thousands of RNAs (2, 3) and, for particular genes, represses nonconserved cryptic exons in a species- (4) and cell-type–specific manner (5, 6).”
BackgroundALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair
Klim, J. R., Williams, L. A., Limone, F., Guerra San Juan, I., Davis-Dusenbery, B. N., Mordes, D. A., Burberry, A., Steinbaugh, M. J., Gamage, K. K., Kirchner, R., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-018-0300-4 · Cited by 653 · cited 10×
“Data from Klim et al (7), was downloaded from Gene Expression Omnibus (GEO) accession GSE121569.”
BackgroundMethodInfluentialMelamed, Z., López-Erauskin, J., Baughn, M. W., Zhang, O., Drenner, K., Sun, Y., Freyermuth, F., McMahon, M. A., Beccari, M. S., Artates, J. W., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-018-0293-z · Cited by 635 · cited 6×
“Using coordinates from the Klim (7) and Melamed (8) publications, the TDP-43–associated junction of the novel truncated STMN2 isoform was extracted from the matrix.”
BackgroundMethodInfluentialCRISPR Interference-Based Platform for Multimodal Genetic Screens in Human iPSC-Derived Neurons
Tian, R., Gachechiladze, M. A., Ludwig, C. H., Laurie, M. T., Hong, J. Y., Nathaniel, D., Prabhu, A. V., Fernandopulle, M. S., Patel, R., Abshari, M., et al. (2019) · Neuron · doi:10.1016/j.neuron.2019.07.014 · Cited by 543
Self-citationJiang, J., Zhu, Q., Gendron, T. F., Saberi, S., McAlonis-Downes, M., Seelman, A., Stauffer, J. E., Jafar-nejad, P., Drenner, K., Schulte, D., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.04.006 · Cited by 536 · cited 1×
“described immunoassay.(32-34) While the levels of full-length STMN2 did not associate with pTDP-43 levels (β: 0.”
BackgroundSelf-citationNeuropathological background of phenotypical variability in frontotemporal dementia
Josephs, K. A., Hodges, J. R., Snowden, J. S., Mackenzie, I. R., Neumann, M., Mann, D. M., & Dickson, D. W. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0839-6 · Cited by 459 · cited 1×
“At present, 5 subtypes of FTLD-TDP (A–E) have been identified (15, 20–23), with types A–C accounting for more than 95% of all FTLD-TDP cases (24).”
BackgroundSelf-citationHigashi, S., Iseki, E., Yamamoto, R., Minegishi, M., Hino, H., Fujisawa, K., Togo, T., Katsuse, O., Uchikado, H., Furukawa, Y., et al. (2007) · Brain Research · doi:10.1016/j.brainres.2007.09.048 · Cited by 419
Uryu, K., Nakashima-Yasuda, H., Forman, M. S., Kwong, L. K., Clark, C. M., Grossman, M., Miller, B. L., Kretzschmar, H. A., Lee, V. M.-Y., Trojanowski, J. Q., et al. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31817713b5 · Cited by 382 · cited 1×
“Indeed, up to 67% of patients with AD develop TDP-43 inclusions and, compared to AD patients without TDP-43 pathology, they are cognitively and functionally worse, suggesting that abnormal TDP-43 causes a modified AD phenotype (37-46).”
BackgroundThe GTEx Consortium atlas of genetic regulatory effects across human tissues
Aguet, F., Barbeira, A. N., Bonazzola, R., Brown, A., Castel, S. E., Jo, B., Kasela, S., Kim-Hellmuth, S., Liang, Y., Oliva, M., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/787903 · Cited by 366
Self-citationPhosphorylated TDP-43 in Alzheimer’s disease and dementia with Lewy bodies
Arai, T., Mackenzie, I. R. A., Hasegawa, M., Nonoka, T., Niizato, K., Tsuchiya, K., Iritani, S., Onaya, M., & Akiyama, H. (2009) · Acta Neuropathologica · doi:10.1007/s00401-008-0480-1 · Cited by 345 · cited 1×
“Indeed, up to 67% of patients with AD develop TDP-43 inclusions and, compared to AD patients without TDP-43 pathology, they are cognitively and functionally worse, suggesting that abnormal TDP-43 causes a modified AD phenotype (37-46).”
BackgroundDipeptide repeat protein pathology in C9ORF72 mutation cases: clinico-pathological correlations
Mackenzie, I. R., Arzberger, T., Kremmer, E., Troost, D., Lorenzl, S., Mori, K., Weng, S.-M., Haass, C., Kretzschmar, H. A., Edbauer, D., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1181-y · Cited by 345 · cited 1×
“It is also notable that TDP-43 morphology and distribution are associated with clinical phenotypes and neurodegeneration in key anatomical regions, such as frontal and temporal cortices in FTLD-TDP (13).”
BackgroundTam, O. H., Rozhkov, N. V., Shaw, R., Kim, D., Hubbard, I., Fennessey, S., Propp, N., Phatnani, H., Kwan, J., Sareen, D., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.09.066 · Cited by 327 · cited 1×
“Age at death (yr) 82 (55, 99) 69 (52, 86) 72 (49, 100) 76 (50, 100) 67 (49, 98) 74 (60, 84) 63 (61, 64)”
Self-citationMackenzie, I. R. A., Baborie, A., Pickering-Brown, S., Plessis, D. D., Jaros, E., Perry, R. H., Neary, D., Snowden, J. S., & Mann, D. M. A. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0138-9 · Cited by 323 · cited 1×
“FTLD-TDP type A, the most common subtype, is characterized by the presence of all the inclusion types mentioned above, whereas types B–E are characterized by the presence of a predominant inclusion type (19, 22).”
BackgroundSampathu, D. M., Neumann, M., Kwong, L. K., Chou, T. T., Micsenyi, M., Truax, A., Bruce, J., Grossman, M., Trojanowski, J. Q., & Lee, V. M.-Y. (2006) · The American Journal of Pathology · doi:10.2353/ajpath.2006.060438 · Cited by 322 · cited 1×
“Patients with FTLD-TDP can be further classified into different pathological subtypes on the basis of the morphology and distribution of the TDP-43 inclusions observed (15, 16).”
BackgroundDavidson, Y., Kelley, T., Mackenzie, I. R. A., Pickering-Brown, S., Du Plessis, D., Neary, D., Snowden, J. S., & Mann, D. M. A. (2007) · Acta Neuropathologica · doi:10.1007/s00401-006-0189-y · Cited by 299 · cited 1×
“Patients with FTLD-TDP can be further classified into different pathological subtypes on the basis of the morphology and distribution of the TDP-43 inclusions observed (15, 16).”
BackgroundThe neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin gene
Mackenzie, I. R. A., Baker, M., Pickering-Brown, S., Hsiung, G.-Y. R., Lindholm, C., Dwosh, E., Gass, J., Cannon, A., Rademakers, R., Hutton, M., et al. (2006) · Brain · doi:10.1093/brain/awl271 · Cited by 297 · cited 1×
“Furthermore, some FTLD-TDP subtypes are associated with particular mutations (20, 25, 26).”
BackgroundSelf-citationLee, E. B., Porta, S., Michael Baer, G., Xu, Y., Suh, E., Kwong, L. K., Elman, L., Grossman, M., Lee, V. M.-Y., Irwin, D. J., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1679-9 · Cited by 259 · cited 1×
“E) have been identified (15, 20-23), with types A-C accounting for more than 95% of all FTLD-”
BackgroundAbnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype
Josephs, K. A., Whitwell, J. L., Knopman, D. S., Hu, W. T., Stroh, D. A., Baker, M., Rademakers, R., Boeve, B. F., Parisi, J. E., Smith, G. E., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000304041.09418.b1 · Cited by 253
Self-citationJosephs, K. A., Dickson, D. W., Tosakulwong, N., Weigand, S. D., Murray, M. E., Petrucelli, L., Liesinger, A. M., Senjem, M. L., Spychalla, A. J., Knopman, D. S., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30284-3 · Cited by 252 · cited 1×
“Indeed, up to 67% of patients with AD develop TDP-43 inclusions and, compared to AD patients without TDP-43 pathology, they are cognitively and functionally worse, suggesting that abnormal TDP-43 causes a modified AD phenotype (37-46).”
BackgroundSelf-citationMutation within TARDBP leads to Frontotemporal Dementia without motor neuron disease
Borroni, B., Bonvicini, C., Alberici, A., Buratti, E., Agosti, C., Archetti, S., Papetti, A., Stuani, C., Di Luca, M., Gennarelli, M., et al. (2009) · Human Mutation · doi:10.1002/humu.21100 · Cited by 241
Dynamic regulation of SCG10 in regenerating axons after injury
Shin, J. E., Geisler, S., & DiAntonio, A. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2013.11.007 · Cited by 208 · cited 1×
“Recently, 2 groups independently found that TDP-43 is required for the correct splicing and expression of stathmin-2 (STMN2) (7, 8), a microtubule-associated protein involved in axonal regeneration (9).”
BackgroundCotto, K. C., Feng, Y.-Y., Ramu, A., Richters, M. M., Freshour, S. L., Skidmore, Z. L., Xia, H., McMichael, J. F., Kunisaki, J., Campbell, K. M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37266-6 · Cited by 199
Josephs, K. A., Ahmed, Z., Katsuse, O., Parisi, J. F., Boeve, B. F., Knopman, D. S., Petersen, R. C., Davies, P., Duara, R., Graff-Radford, N. R., et al. (2007) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/nen.0b013e31803020cf · Cited by 183 · cited 1×
“Furthermore, some FTLD-TDP subtypes are associated with particular mutations (20, 25, 26).”
BackgroundSelf-citationFratta, P., Sivakumar, P., Humphrey, J., Lo, K., Ricketts, T., Oliveira, H., Brito‐Armas, J. M., Kalmar, B., Ule, A., Yu, Y., et al. (2018) · The EMBO Journal · doi:10.15252/embj.201798684 · Cited by 170 · cited 20×
“Dafinca R, et al. Impairment of mitochondrial calcium buffering links mMutations in C9ORF72 and TARDBP in iPS-derived motor neurons from patients with ALS/FTD. Stem Cell Reports.”
BackgroundInfluentialSelf-citationTAR DNA‐binding protein 43 and pathological subtype of Alzheimer's disease impact clinical features
Josephs, K. A., Whitwell, J. L., Tosakulwong, N., Weigand, S. D., Murray, M. E., Liesinger, A. M., Petrucelli, L., Senjem, M. L., Ivnik, R. J., Parisi, J. E., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24493 · Cited by 147 · cited 1×
“Indeed, up to 67% of patients with AD develop TDP-43 inclusions and, compared to AD patients without TDP-43 pathology, they are cognitively and functionally worse, suggesting that abnormal TDP-43 causes a modified AD phenotype (37-46).”
BackgroundSelf-citationTowards a TDP-43-Based Biomarker for ALS and FTLD
Feneberg, E., Gray, E., Ansorge, O., Talbot, K., & Turner, M. R. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-0947-6 · Cited by 146 · cited 1×
“Although TDP-43 represents an attractive biomarker candidate to fulfill these needs, efforts to develop sufficiently sensitive immunoassays for the detection of TDP-43 or its pathological forms in biofluids and that reliably differentiate between individuals with and without TDP-43 pathology have proven disappointing…”
BackgroundSelf-citationReview: neuropathology of non-tau frontotemporal lobar degeneration
Neumann, M., & Mackenzie, I. R. A. (2019) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12526 · Cited by 144 · cited 1×
“ALS is a motor neuron disease (MND), whereas patients with FTD present clinically with 1 or more of the FTD syndromes characterized by behavior, executive function, language, and motor impairments (10).”
BackgroundTemporal lobar predominance of TDP-43 neuronal cytoplasmic inclusions in Alzheimer disease
Hu, W. T., Josephs, K. A., Knopman, D. S., Boeve, B. F., Dickson, D. W., Petersen, R. C., & Parisi, J. E. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0400-4 · Cited by 134 · cited 1×
“Indeed, up to 67% of patients with AD develop TDP-43 inclusions and, compared to AD patients without TDP-43 pathology, they are cognitively and functionally worse, suggesting that abnormal TDP-43 causes a modified AD phenotype (37-46).”
BackgroundSelf-citationSchludi, M. H., Becker, L., Garrett, L., Gendron, T. F., Zhou, Q., Schreiber, F., Popper, B., Dimou, L., Strom, T. M., Winkelmann, J., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1711-0 · Cited by 131 · cited 1×
“described immunoassay.(32-34) While the levels of full-length STMN2 did not associate with pTDP-43 levels (β: 0.”
BackgroundSelf-citationDafinca, R., Barbagallo, P., Farrimond, L., Candalija, A., Scaber, J., Ababneh, N. A., Sathyaprakash, C., Vowles, J., Cowley, S. A., & Talbot, K. (2020) · Stem Cell Reports · doi:10.1016/j.stemcr.2020.03.023 · Cited by 131 · cited 1×
“) or controls (Controls) from two independent groups in Edinburgh (dataset labeled “c”; N=7 TDP-43 KD, N=4 Controls) and Oxford (dataset labeled “d”, N=10 TDP-43 KD, N=4 Controls) (73).”
BackgroundSelf-citationNeurons selectively targeted in frontotemporal dementia reveal early stage TDP-43 pathobiology
Nana, A. L., Sidhu, M., Gaus, S. E., Hwang, J.-H. L., Li, L., Park, Y., Kim, E.-J., Pasquini, L., Allen, I. E., Rankin, K. P., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-018-1942-8 · Cited by 128 · cited 8×
“ALS samples were divided into the following subcategories using the available Consortium metadata: ALS with or without reported SOD1 mutations (ALS-TDP and ALS-SOD1); ALS with frontotemporal dementia (ALS-FTLD); and ALS with AD (ALS-AD).”
BackgroundInfluentialEvaluation of subcortical pathology and clinical correlations in FTLD-U subtypes
Josephs, K. A., Stroh, A., Dugger, B., & Dickson, D. W. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0547-7 · Cited by 126 · cited 1×
“FTLD-TDP type A, the most common subtype, is characterized by the presence of all the inclusion types mentioned above, whereas types B–E are characterized by the presence of a predominant inclusion type (19, 22).”
BackgroundSelf-citationRepetitive element transcripts are elevated in the brain of C9orf72 ALS/FTLD patients
Prudencio, M., Gonzales, P. K., Cook, C. N., Gendron, T. F., Daughrity, L. M., Song, Y., Ebbert, M. T. W., van Blitterswijk, M., Zhang, Y.-J., Jansen-West, K., et al. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx233 · Cited by 122 · cited 1×
“from frozen human postmortem frontal cortex tissues (33).”
BackgroundSelf-citationThe landscape of multiscale transcriptomic networks and key regulators in Parkinson’s disease
Wang, Q., Zhang, Y., Wang, M., Song, W.-M., Shen, Q., McKenzie, A., Choi, I., Zhou, X., Pan, P.-Y., Yue, Z., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13144-y · Cited by 121 · cited 1×
“Indeed, a recent report found that full-length STMN2 RNA levels were also decreased in the brains of patients with Parkinson’s disease (36), possibly arguing for the use of STMN2 levels as a neurodegenerative disease biomarker.”
BackgroundQuantitative analysis of cryptic splicing associated with TDP-43 depletion
Humphrey, J., Emmett, W., Fratta, P., Isaacs, A. M., & Plagnol, V. (2017) · BMC Medical Genomics · doi:10.1186/s12920-017-0274-1 · Cited by 115 · cited 1×
“TDP-43 binds thousands of RNAs (2, 3) and, for particular genes, represses nonconserved cryptic exons in a species- (4) and cell-type–specific manner (5, 6).”
BackgroundSelf-citationqSVA framework for RNA quality correction in differential expression analysis
Jaffe, A. E., Tao, R., Norris, A. L., Kealhofer, M., Nellore, A., Shin, J. H., Kim, D., Jia, Y., Hyde, T. M., Kleinman, J. E., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1617384114 · Cited by 114 · cited 1×
“affect the estimation of transcript abundance (65, 66), and we rea-”
BackgroundSelf-citationTdp-43 cryptic exons are highly variable between cell types
Jeong, Y. H., Ling, J. P., Lin, S. Z., Donde, A. N., Braunstein, K. E., Majounie, E., Traynor, B. J., LaClair, K. D., Lloyd, T. E., & Wong, P. C. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0144-x · Cited by 112 · cited 1×
“TDP-43 binds thousands of RNAs (2, 3) and, for particular genes, represses nonconserved cryptic exons in a species- (4) and cell-type–specific manner (5, 6).”
BackgroundKadokura, A., Yamazaki, T., Lemere, C. A., Takatama, M., & Okamoto, K. (2009) · Neuropathology · doi:10.1111/j.1440-1789.2009.01017.x · Cited by 105
Koga, S., Kouri, N., Walton, R. L., Ebbert, M. T. W., Josephs, K. A., Litvan, I., Graff-Radford, N., Ahlskog, J. E., Uitti, R. J., van Gerpen, J. A., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1878-z · Cited by 73 · cited 9×
“No treatment for frontotemporal dementia (FTD), the second most common type of early-onset dementia, is available, but therapeutics are being investigated to target the 2 main proteins associated with FTD pathological subtypes: TDP-43 (FTLD-TDP) and tau (FTLD-tau).”
BackgroundInfluentialSelf-citationTan, R. H., Shepherd, C. E., Kril, J. J., McCann, H., McGeachie, A., McGinley, C., Affleck, A., & Halliday, G. M. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-33 · Cited by 67 · cited 1×
“E) have been identified (15, 20-23), with types A-C accounting for more than 95% of all FTLD-”
BackgroundHatanpaa, K. J., Bigio, E. H., Cairns, N. J., Womack, K. B., Weintraub, S., Morris, J. C., Foong, C., Xiao, G., Hladik, C., Mantanona, T. Y., et al. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31816a12a6 · Cited by 62 · cited 1×
“and as fine neurites in the hippocampus (14, 17-20).”
BackgroundKadokura, A., Yamazaki, T., Kakuda, S., Makioka, K., Lemere, C. A., Fujita, Y., Takatama, M., & Okamoto, K. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.06.024 · Cited by 60
Cotto, K. C., Feng, Y.-Y., Ramu, A., Richters, M., Freshour, S. L., Skidmore, Z. L., Xia, H., McMichael, J. F., Kunisaki, J., Campbell, K. M., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/436634 · Cited by 55
Jackson, J. L., Finch, N. A., Baker, M. C., Kachergus, J. M., DeJesus-Hernandez, M., Pereira, K., Christopher, E., Prudencio, M., Heckman, M. G., Thompson, E. A., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-0359-8 · Cited by 49 · cited 1×
“and previously used to normalize human brain transcripts (71).”
Self-citation
Cited by
TDP-43 represses cryptic exon inclusion in the FTD-ALS gene UNC13A
Ma, X. R., Prudencio, M., Koike, Y., Vatsavayai, S. C., Kim, G., Harbinski, F., Briner, A., Rodriguez, C. M., Guo, C., Akiyama, T., et al. (2022) · Nature · doi:10.1038/s41586-022-04424-7 · Cited by 574
“This work was supported by NIH grants R35NS097263(10) (A.”
BackgroundSelf-citationTDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A
Brown, A.-L., Wilkins, O. G., Keuss, M. J., Kargbo-Hill, S. E., Zanovello, M., Lee, W. C., Bampton, A., Lee, F. C. Y., Masino, L., Qi, Y. A., et al. (2022) · Nature · doi:10.1038/s41586-022-04436-3 · Cited by 529
“Our approach, based on our previous work (Prudencio, 2020), has the advantage of assessing TDP-43 pathology and UNC13A mis-splicing within the same sample.”
Self-citationMead, R. J., Shan, N., Reiser, H. J., Marshall, F., & Shaw, P. J. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00612-2 · Cited by 505
Triad of TDP43 control in neurodegeneration: autoregulation, localization and aggregation
Tziortzouda, P., Van Den Bosch, L., & Hirth, F. (2021) · Nature Reviews Neuroscience · doi:10.1038/s41583-021-00431-1 · Cited by 267
Mechanism of STMN2 cryptic splice-polyadenylation and its correction for TDP-43 proteinopathies
Baughn, M. W., Melamed, Z., López-Erauskin, J., Beccari, M. S., Ling, K., Zuberi, A., Presa, M., Gonzalo-Gil, E., Maimon, R., Vazquez-Sanchez, S., et al. (2023) · Science · doi:10.1126/science.abq5622 · Cited by 239
Metadata
- Authors
- Prudencio, M., Humphrey, J., Pickles, S., Brown, A.-L., Hill, S. E., Kachergus, J. M., Shi, J., Heckman, M. G., Spiegel, M. R., Cook, C., Song, Y., Yue, M., Daughrity, L. M., Carlomagno, Y., Jansen-West, K., de Castro, C. F., DeTure, M., Koga, S., Wang, Y.-C., Sivakumar, P., Bodo, C., Candalija, A., Talbot, K., Selvaraj, B. T., Burr, K., Chandran, S., Newcombe, J., Lashley, T., Hubbard, I., Catalano, D., Kim, D., Propp, N., Fennessey, S., Fagegaltier, D., Phatnani, H., Secrier, M., Fisher, E. M. C., Oskarsson, B., van Blitterswijk, M., Rademakers, R., Graff-Radford, N. R., Boeve, B. F., Knopman, D. S., Petersen, R. C., Josephs, K. A., Thompson, E. A., Raj, T., Ward, M., Dickson, D. W., Gendron, T. F., Fratta, P., & Petrucelli, L.
- Affiliations
- Mayo Clinic (US)
- Icahn School of Medicine at Mount Sinai (US)
- UCL Queen Square Institute of Neurology (GB)
- University of Oxford (GB)
- UK Dementia Research Institute (GB)
- National Hospital for Neurology and Neurosurgery (GB)
- New York Genome Center (US)
- University College London (GB)
- National Institutes of Health (US)
- Corresponding author
- Fratta, Pietro
- Petrucelli, Leonard
- ORCID
- Prudencio, Mercedes
- Humphrey, Jack
- Pickles, Sarah
- Brown, Anna-Leigh
- Hill, Sarah E.
- Shi, J.
- Heckman, Michael G.
- Spiegel, Matthew R.
- Cook, Casey
- Song, Yuping
- Daughrity, Lillian M.
- Carlomagno, Yari
- Jansen-West, Karen
- DeTure, Michael
- Koga, Shunsuke
- Wang, Ying-Chih
- Bodo, Cristian
- Candalija, Ana
- Talbot, Kevin
- Selvaraj, Bhuvaneish T.
- Chandran, Siddharthan
- Newcombe, Jia
- Lashley, Tammaryn
- Hubbard, Isabel
- Propp, Nadia
- Fennessey, Samantha
- Fagegaltier, Delphine
- Phatnani, Hemali
- Secrier, Maria
- Fisher, Elizabeth M.C.
- Oskarsson, Björn
- van Blitterswijk, Marka
- Rademakers, Rosa
- Boeve, Bradley F.
- Knopman, David S.
- Petersen, Ronald C.
- Josephs, Keith A.
- Thompson, E. Aubrey
- Raj, Towfique
- Ward, Michael
- Dickson, Dennis W.
- Gendron, Tania F.
- Fratta, Pietro
- Petrucelli, Leonard
- Venue
- Journal of Clinical Investigation
- Published
- 2020-10-19
- Volume
- 130
- Issue
- 11
- Pages
- 6080-6092
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC7598060
- OpenAlex
- W3049616059
- Cited by
- 231
- References
- 68
- Citations by year
- 2026: 36 · 2025: 42 · 2024: 54 · 2023: 48 · 2022: 30 · 2021: 19 · 2020: 2
- FWCI
- 10.66
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- NINDS and others, see below (see below)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- STMN2, TDP-43 pathology, frontotemporal dementia, FTLD-TDP, FTLD-tau, diagnostic biomarkers, iPSC-derived neurons, TARDBP mutations, phosphorylated TDP-43, age of disease onset, progressive supranuclear palsy, RNA expression
- MeSH terms
- DNA-Binding Proteins, Female, Frontal Lobe, Humans, Male, Middle Aged, Mutation, Biomarkers, Stathmin, Induced Pluripotent Stem Cells, Frontotemporal Dementia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.